Main Category: HIV / AIDS
Also Included In: MRSA / Drug Resistance
Article Date: 15 Jun 2012 – 1:00 PDT

email to a friend   printer friendly   opinions  

<!– rate article

Patient / Public:

4.5 (2 votes)

Healthcare Prof:

4 (1 votes)

Scientists at The Scripps Research Institute have used a powerful new chemical-screening method to find compounds that inhibit the activity of human immunodeficiency virus (HIV), the virus that causes AIDS. Unlike existing anti-HIV drugs, the compounds bind to a protein called “nucelocapsid,” which is unlikely to mutate into drug-resistant forms.

“Most of the nucleocapsid-inhibiting compounds that have been identified to date are very toxic, but our screening method identified inhibitors that are less toxic and thus more likely to lead to useful drugs,” said Scripps Research Associate Professor Bruce Torbett. Torbett is the senior author of the new report, which appears in the print issue of the Journal of Medicinal Chemistry.

HIV’s nucleocapsid protein binds to the viral genome to package and protect it, and plays a key role in the assembly of new virus copies, as well as in the reverse transcription of the viral genome into DNA. It has long been a target of HIV drug developers because it grabs hold of the viral genome using protein structures – known as zinc knuckles – that can’t change much without losing their functionality. It thus is thought to have little room to mutate into drug-resistant forms, in contrast with other HIV proteins.


Screening Out Toxicity

However, despite almost two decades of research, there are still no FDA-approved drugs that target HIV’s nucleocapsid protein and its zinc knuckle structures. One reason is that similar structures exist on many healthy cellular proteins; thus compounds that target them are apt to have unwanted side effects. “When researchers have targeted these nucleocapsid zinc knuckles in the past, they’ve usually ended up producing toxicity,” Torbett said.

To increase the chances of finding safe compounds, Torbett and his colleagues – postdoctoral researcher Sebastian Breuer, the study’s first author, and Max Chang and Jinyun Yuan, also postdoctoral researchers – began with the Maybridge HitFinder Collection, a library of 14,400 chemical compounds from which many broadly toxic molecules have already been excluded. The Scripps Research Molecular Screening Center maintains the latest robotic equipment for quickly applying chemical tests to such libraries. With the help of screening expert Scripps Research Professor Hugh Rosen, Screening Center Staff Scientist Steven Brown, and Research Assistant Jacqueline Lohse, Breuer applied a special combination of screening tests to the Maybridge library to rapidly zero in on effective and safe nucleocapsid-inhibiting compounds.

The first screening test employed a technique known as fluorescence polarization to measure the ability of each compound in the library to displace the binding of the viral genome to the nucleocapsid protein. (The study focused on the virus type HIV-1, which accounts for the vast majority of HIV infections outside West Africa.) The second test, using differential scanning fluorimetry, was applied to the 101 compounds that passed the first test; it identified those that perform the displacement by binding strongly to the nucleocapsid protein rather than to the viral genome.

After eliminating the weaker and more toxic candidates with further tests, Breuer, Torbett, and their colleagues ended up with 10 compounds. Detailed analyses of these yielded two that were sufficiently powerful at inhibiting viral infectivity in cell culture tests, without being unacceptably toxic.

“We went very quickly from having a concept to having these two inhibitors with demonstrated anti-HIV activity in cells,” said Torbett.


Searching for the ‘Sweet Spot’

With his Scripps Research colleagues M. G. Finn and Valery Fokin, Torbett now plans to evaluate compounds that are closely related to the two inhibitors to see if the scientists can find any that are even more safe and effective. Torbett and colleagues also plan to apply the same combination-screening method to larger compound libraries to identify entirely new nucleocapsid-inhibiting compounds.

To gain a better understanding of how these inhibitors work, Torbett is also collaborating with Scripps Research structural biologists, including David Stout and Arthur Olson, and virologist John Elder to perform X-ray crystallography studies of the inhibitors in combination with the HIV nucleocapsid protein.

“The overall goal here is to find a ‘sweet spot’ on the nucleocapsid protein that can be targeted effectively by a small-molecule drug without causing toxicity,” Torbett said.

  • Additional
  • References
  • Citations

Please use one of the following formats to cite this article in your essay, paper or report:

MLA


APA


Please note: If no author information is provided, the source is cited instead.



Add Your Opinion On This Article

‘New Drug-Screening Method Yields Long-Sought Anti-HIV Compounds’

Please note that we publish your name, but we do not publish your email address. It is only used to let
you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care
professional. For more information, please read our terms and conditions.

Privacy Policy |
Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
MNT (logo) is the registered EU trade mark of MediLexicon Int. Limited.

back to top | home |
privacy policy

MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
MNT (logo) is the registered EU trade mark of MediLexicon Int. Limited.

Article source: http://www.medicalnewstoday.com/releases/246591.php

 

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

TEAM 25:40
Help become part of the solution by running for 25:40. As a fundraising partner this is your place to share your story about your race, discover races in your area, and network with likeminded people.
THE AIDS IMPACT
The Sub-Saharan AIDS epidemic has a devastating effect on millions of families. Consider that 5.3 million adults and children live with HIV/AIDS in South Africa alone. Discover the hard facts about AIDS, and help become a part of the solution.
CURRENT PROJECTS
25:40’s current focus is on children living in rural areas of South Africa’s Eastern Cape. We have selected this area as our place of initial focus due to its extreme poverty, lack of resources and lack of attention from the outside world.